2026-08-18 15:55

Recently, Dongcheng Andyke (Shanxi), a subsidiary of Dongcheng Pharmaceutical's wholly-owned subsidiary Dongcheng Andyke, was issued the Radioactive Drug Production License by the Shanxi Provincial Medical Products Administration. This marks that the Shanxi Jinzhong radiopharmaceutical production center has met production requirements, adding another facility to Dongcheng Pharmaceutical's radiopharmaceutical production network. As one of China's leading nuclear medicine companies, the Group has adhered to a layout strategy of "networking for short half-life products and base-ization for long half-life products," and has built a domestically leading radiopharmaceutical production and distribution network. To date, the Group has 33 operational radiopharmaceutical production centers.

As a "heparin expert and radiopharmaceutical pioneer," Dongcheng Pharmaceutical will continue to deepen its cultivation of the nuclear medicine sector, comprehensively build the Dongcheng nuclear medicine ecosystem, and leverage its advantages in innovative R&D, product pipeline, and production and distribution networks to continuously meet clinical needs and benefit patients.

Source link: https://www.cinie.net/article/61251.html

This information is provided for industry reference only. All rights are reserved by the original platform. For copyright issues, please contact us for removal.